Abstract: A door safety device generally includes a mounting member for coupling the device to a door and a blocking member for preventing complete closure of the door when the mounting member is attached to the door and the device is in a blocking configuration. The device can also include an intermediate member coupled between the mounting member and the blocking member. The intermediate member defines a first hinge axis extending in a direction parallel to the surface of the door and parallel to an edge of the door. The blocking member is movable (e.g., rotatable or revolvable) about the first hinge axis, at least when the mounting member is coupled to the door and the device is in a blocking configuration, so as to inhibit the transfer of detachment forces from the blocking member to the mounting member upon impact.

Abstract: A door safety device for either a hinged or a sliding door which when closing places the vertical door side edge in a position abutting the vertical face of either of two sides of a door jamb, or the vertical face of another sliding door, or the threshold end of a sliding door track. The device employs a body in pivotal engagement with a resilient body for positioning the body in an as-used position between the door side edge and the vertical face to maintain a gap to prevent finger crushing. A curved leading edge provides a deflection of impact forces upon the resilient body to prevent marring of the vertical face of the door jamb or threshold.

Abstract: A device for preventing injury between the surfaces of the leading edge of a closing door and an edge of a recess surrounded by a door jamb which surrounds the door when closed. The device features a housing and two sequential translating members which contact the recess edge and maintain a gap between it and the door edge for a dwell time which the second member remains between the two edges.

Abstract: A door safety device for either a hinged or a sliding door which when closing places the vertical door side edge in a position abutting the vertical face of either of two sides of a door jamb, or the vertical face of another sliding door, or the threshold end of a sliding door track. The device employs a body in pivotal engagement with a resilient body for positioning the body in an as-used position between the door side edge and the vertical face to maintain a gap to prevent finger crushing. A curved leading edge provides a deflection of impact forces upon the resilient body to prevent marring of the vertical face of the door jamb or threshold.

Abstract: A device for preventing injury between the surfaces of the leading edge of a closing door and an edge of a recess surrounded by a door jamb which surrounds the door when closed. The device features a housing and two sequential translating members which contact the recess edge and maintain a gap between it and the door edge for a dwell time which the second member remains between the two edges.

Abstract: A door safety device for either a hinged or a sliding door which when closing places the vertical door side edge in a position abutting the vertical face of either of two sides of a door jamb, or the vertical face of another sliding door, or the threshold end of a sliding door track. The device employs a body in pivotal engagement with a resilient body for positioning the body in an as-used position between the door side edge and the vertical face to maintain a gap to prevent finger crushing. A curved leading edge provides a deflection of impact forces upon the resilient body to prevent marring of the vertical face of the door jamb or threshold.

Abstract: The present invention relates to a compound of diclofenac-tramadol salt in 1:1 ratio and a pharmaceutical formulation comprising such compound. The present invention also relates to a method for treating a patient with moderate to moderately severe pain. The method comprises: identifying a patient suffering from moderate to moderately severe pain with pain intensity scale of 5-9, and administering to said patient the diclofenac-tramadol salt, in an effective amount. The method is particularly useful in treating postoperative pain after Cesarean, postoperative pain after non-Cesarean surgeries, cancer pain, osteoarthritis pain, or rheumatoid arthritis pain.

Abstract: The present invention is directed to a bi-folding wheelchair (10) with side frames (12) and (14) that fold together with a compound scissor action moving the large rear wheels (96) to a central location while the backrest (50) is folding downwardly. Two separate locking mechanisms (28) and (40) hold the frame apart in the upright position while two additional locking mechanisms (77) hold the backrest (50) upright or down in the collapsed position. All the major components of the conventional wheelchairs like the foot rests, the arm rests, large wheels, caster wheels and the backrest fit into a compact package narrower than the unfolded wheelchair and slightly larger than the diameter of the back wheels with all parts folding in and out simultaneously. The large rear wheel assemblies can be quickly removed further reducing the size and weight of the device for shipping or storage.

Abstract: Compounds having structure (1) wherein R1 is —H a protecting group, a linker or a binding partner; and R2 and R34 are as defined in the specification. The invention also provides intermediates and methods make the structure (1) compounds, as well as methods to use the compounds as labels in diagnostic assays and to enhance binding to complementary bases.

Abstract: A method for treating an angiogenesis-related disorder. The method includes administrating to a subject in need thereof an effective amount of a compound of the formula: Each of Ar1, Ar2, and Ar3, independently, is phenyl, thienyl, furyl, pyrrolyl, pyridinyl, or pyrimidinyl; each of R1, R2, R3, R4, R5, and R6, independently, is R, nitro, halogen, C(O)OR, C(O)SR, C(O)NRR?, (CH2)mOR, (CH2)mSR, (CH2)mNRR?, (CH2)mCN, (CH2)mC(O)OR, (CH2)mCHO, (CH2)mCH?NOR, or R1 and R2 together, R3 and R4 together, or R5 and R6 together are O(CH2)mO, in which each of R and R?, independently, is H or C1˜C6 alkyl; and m is 0, 1, 2, 3, 4, 5, or 6, and n is 0, 1, 2, or 3.

Abstract: A method for enhancing learning and memory or treating amnesia. The method includes administrating to a subject in need thereof a compound of the formula (I): A is H, R, or ?each of Ar1, Ar2, and Ar3, independently, is phenyl, thienyl, furyl, or pyrrolyl; each of R1, R2, R3, R4, R5, and R6, independently, is H, nitro, halogen, R, OH, OR, C(O)OH, C(O)OR, C(O)SH, C(O)SR, C(O)NH2, C(O)NHR, C(O)NRR?, ROH, ROR?, RSH, RSR?, ROC(O)R?OH, NHR, NRR?, RNHR?, or RNR?R?; or R1 and R2 together, R3 and R4 together, or R5 and R6 together are ORO; wherein each of R, R?, and R?, independently is C1˜C6 alkyl; and n is 1, 2, or 3. The compound is in an effective amount for enhancing learning and memory or treating amnesia.

Abstract: The present invention provides novel pharmaceutical compositions for azole antimicrobial drugs such as itraconazole, saperconazole, ketoconazole, and fluconazole. The pharmaceutical compositions are in the form of pellets which comprise a core and a drug emulsion layer, and optionally, a protective layer. The drug emulsion layer contains the azole antimicrobial drug, an emulsifier, a binder, and an absorbent aid. The preferred emulsifier is vitamin E polyethylene glycol succinate. The preferred binder is hydroxypropyl methylcellulose. The preferred absorbent aid is DL malic acid. The drug is dissolved in organic solvents. The preferred organic solvents are ethanol and methylene chloride. The protective layer contains polyethylene glycol (PEG) 20,000, which is coated on the drug emulsion layer.

Abstract: The present invention provides pharmaceutical formulations which contain (a) an inert core of sugar, sugar and starch, or microcrystalline cellulose, (b) a drug emulsion layer which is made from mixing a free base of benzimidazole derivative (such as omeprazole or lansoprazole) with a nonionic surfactant and water, (c) a protective coating which is made of a film-forming compound, and optionally a plasticizer or excipient, and (d) an enteric coating which is made of a pharmaceutically acceptable polymer and a plasticizer. Optionally, a basic amino acid can be added to the drug emulsion layer or the protective coating. The present invention also provides the method for making the pharmaceutical formulations.